Abstract
Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960s but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990s, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.
Current Drug Targets
Title: Ketamine: New Indications for an Old Drug
Volume: 6 Issue: 7
Author(s): M. G. Annetta, D. Iemma, C. Garisto, C. Tafani and R. Proietti
Affiliation:
Keywords: ketamine, analgesia, opioids
Abstract: Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960s but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990s, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.
Export Options
About this article
Cite this article as:
Annetta G. M., Iemma D., Garisto C., Tafani C. and Proietti R., Ketamine: New Indications for an Old Drug, Current Drug Targets 2005; 6(7) . https://dx.doi.org/10.2174/138945005774574533
DOI https://dx.doi.org/10.2174/138945005774574533 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Automated Radiosynthesis and Molecular Docking Studies of Coumarin-
Triazole Hybrid with fluorine-18: A feasibility study
Current Radiopharmaceuticals Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Current Drug Metabolism Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Delineating Somatostatins Neuronal Actions
Current Drug Targets - CNS & Neurological Disorders Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design Foreword
Current Topics in Medicinal Chemistry Pharmacotherapy in Pedatric PTSD: A Developmentally-Focused Review of the Evidence
Current Psychopharmacology Role of Microfluidics in Blood-Brain Barrier Permeability Cell Culture Modeling: Relevance to CNS Disorders
CNS & Neurological Disorders - Drug Targets Application of Efficient Nanoparticles for Early Diagnosis and Treatment of Cancer
Current Drug Metabolism The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Neuropeptide Y as an Endogenous Antiepileptic, Neuroprotective and Pro-Neurogenic Peptide
Recent Patents on CNS Drug Discovery (Discontinued) Antiepileptic Drugs Based on the α-Substituted Amide Group Pharmacophore: From Chemical Crystallography to Molecular Pharmaceutics
Current Pharmaceutical Design Relationship Between Oxidative Stress, Tau Level and Antioxidant Mechanisms of the KEAP-1/NRF-2/HO-1 in Children with Hydrocephalus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics